NCT04261907View on ClinicalTrials.gov

Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection

NATerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

February 11, 2020

Primary Completion Date

April 13, 2020

Study Completion Date

April 13, 2020

Conditions
2019-nCoV
Interventions
DRUG

ASC09/ritonavir group

ASC09/ritonavir(300mg/100mg tablet), one tablet each time, twice daily, for 14 days, +conventional standardized treatment

DRUG

lopinavir/ritonavir group

Lopinavir/ritonavir tablets(200mg / 50mg tablet), two tablets each time, twice daily, for 14 days, +conventional standardized treatment

Trial Locations (1)

310003

The first affiliated hospital, Zhejiang University School of Medicine, Hangzhou

Sponsors
All Listed Sponsors
collaborator

Ascletis Pharmaceuticals Co., Ltd.

INDUSTRY

lead

First Affiliated Hospital of Zhejiang University

OTHER